| Name | Title | Contact Details |
|---|
FzioMed is a San Luis Obispo, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
HealthCarts.com is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs, biologics and vaccines. Unilife has a broad portfolio of injectable drug delivery systems including prefilled syringes, auto-injectors, wearable injectors, drug reconstitution delivery systems, ocular delivery systems and novel devices. Unilife builds long-term partnerships with pharmaceutical and biotechnology companies seeking to leverage our products to enable, enhance and differentiate their injectable therapies. Unilife can develop or customize its device technologies to address the specific drug, commercial and patient needs of its pharmaceutical customers. Unilife’s dynamic business environment, advanced operational capabilities, world-class team and stringent quality processes enables the Company to serve the device innovation needs of its pharmaceutical customers with speed, agility and reliability. A state-of-the-art global headquarters and manufacturing facility in York, PA serves as an integrated center for the seamless design, development, production, quality control, regulatory compliance and commercial supply of its products.
Prevtec Microbia Inc. is a Saint-Hyacinthe, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.